Aptorum Group LtdNASDAQ:APM
- LAST PRICE5.2800
- TODAY'S CHANGE (%)-0.2000 (-3.6496%)
- Bid / Lots5.2300/ 20
- Ask / Lots5.5000/ 5
- Open / Previous Close5.4500 / 5.4800
- Day Range
- 52 Week Range
- Volume27,222
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APM |
|---|---|---|
| 09:32 ET | 1019 | 5.35 |
| 09:39 ET | 237 | 5.4 |
| 09:43 ET | 498 | 5.4 |
| 09:54 ET | 1198 | 5.26 |
| 09:56 ET | 3993 | 5.3 |
| 09:57 ET | 936 | 5.3 |
| 10:01 ET | 100 | 5.16 |
| 10:08 ET | 235 | 5.25 |
| 10:10 ET | 588 | 5.15 |
| 10:12 ET | 100 | 5.2 |
| 10:14 ET | 205 | 5.2 |
| 10:17 ET | 300 | 5.225 |
| 10:30 ET | 300 | 5.2 |
| 10:37 ET | 245 | 5.31 |
| 10:57 ET | 600 | 5.26 |
| 11:13 ET | 500 | 5.26 |
| 11:20 ET | 100 | 5.26 |
| 11:29 ET | 1000 | 5.26 |
| 11:36 ET | 100 | 5.27 |
| 11:49 ET | 100 | 5.26 |
| 11:54 ET | 500 | 5.23 |
| 11:56 ET | 1400 | 5.31 |
| 12:03 ET | 600 | 5.23 |
| 12:14 ET | 200 | 5.3 |
| 12:34 ET | 100 | 5.3 |
| 12:45 ET | 2706 | 5.23 |
| 12:52 ET | 474 | 5.23 |
| 12:56 ET | 700 | 5.23 |
| 02:04 ET | 210 | 5.3 |
| 02:11 ET | 100 | 5.24 |
| 02:22 ET | 100 | 5.24 |
| 02:29 ET | 914 | 5.22 |
| 02:31 ET | 473 | 5.22 |
| 02:36 ET | 300 | 5.235 |
| 02:47 ET | 500 | 5.24 |
| 03:25 ET | 100 | 5.25 |
| 03:48 ET | 300 | 5.28 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aptorum Group Ltd | 28.4M | -1.4x | --- |
Lexaria Bioscience Corp | 28.2M | -3.4x | --- |
Acasti Pharma Inc | 27.5M | -0.6x | --- |
Cyclo Therapeutics Inc | 37.0M | -0.9x | --- |
Vyne Therapeutics Inc | 34.8M | -0.4x | --- |
PolyPid Ltd | 23.1M | -0.2x | --- |
Company Information
Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Company’s lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
Contact Information
- Headquarters
- 17 Hanover SquareLONDON, United Kingdom W1S 1BN
- Phone
- 208-092-9299
- Fax
- 203-928-8277
Executives
- President, Executive Director
- Darren Lui
- Chief Executive Officer, Founder, Executive Director
- Ian Huen
- Chief Financial Officer
- Sabrina Khan
- Chief Medical Officer and Executive Director
- Clark Cheng
- Head of Research and Development
- Thomas Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.4M |
|---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 5.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-3.64 |
Book Value | $4.40 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 23.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,299.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
